Clinical trial / 2002
Glucosamine sulfate retarded joint space narrowing and improved symptoms over 3 years in patients with knee osteoarthritis.
A randomized, double-blind trial assigned 202 patients with knee osteoarthritis to receive oral glucosamine sulfate (1500 mg once daily) or placebo for 3 years. After 3 years, progressive joint space narrowing was -0.19 mm (95% CI, -0.29 to -0.09 mm) with placebo, compared to no average change with glucosamine sulfate (0.04 mm; 95% CI, -0.06 to 0.14 mm; P = .001). Predefined severe narrowings (>0.5 mm) occurred in 5% of glucosamine sulfate patients compared to 14% of placebo patients (P = .05). Glucosamine sulfate also led to a 20% to 25% improvement in symptoms, showing significant final differences on the Lequesne index and WOMAC total index and subscales.
- Study type
- 3-year randomized, placebo-controlled, double-blind study
- Who was studied
- 202 patients with knee osteoarthritis
- What was measured
- Changes in radiographic minimum joint space width and symptom scores (Lequesne and WOMAC indexes)
THE PAPER
Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.
Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Arch Intern Med, 2002.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.